About Us
WaiveDx is a precision health company redefining how advanced diagnostics, AI, and therapeutics converge to serve consumer, legal, and government healthcare markets. Formed as a joint venture between WellGenx (personalized health), Precision Labs (CLIA-certified diagnostics), and Waive IQ (federal contracting and compliance), WaiveDx brings together cutting-edge science and operational excellence under one unified platform.
At the heart of WaiveDx is Nymara™, our proprietary AI engine that powers clinical interpretation, consent automation, regulatory compliance, and custom supplement protocols. This core technology fuels applications like:
NeuDefense™ – behavioral genomic reports used in legal diversion programs with >85% jail avoidance,
WellGenx & Velisce – personalized wellness kits for health optimization and longevity,
PredictIQ™ and Synapta™ – next-gen AI tools for clinical decision support and care modeling.
Our leadership team brings over 100 years of combined experience in biotech, diagnostics, digital health, and commercialization. This operational depth allows Waive DX to move with uncommon speed and precision in regulated markets. From SaaS subscriptions, direct-to-consumer health products, legal bundles, and federal programs, Waive DX is diversified by design.
